Sania Therapeutics

Sania Therapeutics is a biotechnology company developing genetic medicines for diseases caused by dysfunctional neural circuits.

Its approach combines precision AAV delivery to selected neural circuits with tuneable neuromodulation, using human iPSC-derived neural models to direct the evolution of human-centric vectors via its platform.

A second platform enables conditionally activated ion channels controlled by an oral medicine. Lead programmes target motor disorders.